Starpharma Holdings Limited
(ASX:SPL) has announced positive results from further testing of its cancer drug docetaxel.
Further studies have found an improvement in tumour targeting compared to its conventional formulation of the drug known as Taxotere.
Docetaxel is a chemotherapy drug used to treat a wide range of tumours found in the breast, lung and prostate.
Starpharma’s chief says the latest results will extend beyond docetaxel to the application of other anti-cancer agents.
Starpharma Holdings reported a net loss of almost $14 million in the 2012 financial year.
